Plain English Summary
Background and study aims
Sepsis is an infection that can cause organs to fail. Sepsis can cause Acute Kidney Injury (AKI), then causing sepsis shock. It is reported that sepsis patients with mild AKI will increase their mortality. Therefore, for clinicians and patients, how to effectively predict the incidence of AKI associated with sepsis is a major issue. CEUS is an injection of contrast agents in the blood to observe tissue perfusion (the passage of fluids), allowing clinicians to see if the kidneys have been impacted. From Sepsis related AKI, is one of the main causes of low perfusion of renal tissue. Therefore, the aim of this study is to examine if CEUS can be used to observe and predict the occurrence of sepsis related AKI and can improve the survival rate of patients with sepsis.
Who can participate?
Adults aged 18 and older who have sepsis.
What does the study involve?
Participants are allocated to one of two groups. Those in the first group are AKI as determined by AKIN criteria. Those in the second group are the non-AKI group based on the AKIN criteria. Participants undergo CEUS injections and are followed up with ultrasound scans and contrast-enhanced ultrasound examination on the day of injections, one day, three days and seven days after the injection.
What are the possible benefits and risks of participating?
There are no risks or benefits with participating.
Where is the study run from?
This study is being run by the emergency intensive care unit (EICU) of the Emergency Department Sir Run Run Shaw Hospital affliated to the Zhejiang University (China).
When is the study starting and how long is it expected to run for?
August 2017 to September 2019
Who is funding the study?
Zhejiang Provincial Natural Science Foundation of China (China)
Who is the main contact?
Dr Zhongheng Zhang (Public)
The utility of contrast-enhanced ultrasound for the prediction of acute kidney injury after sepsis
CEUS is a method in which an injection of an contrast agent into a blood vessel in order to develop a microvascular approach to observe tissue perfusion. The pathogenesis of sepsis related AKI is mainly the hypoperfusion of renal tissue. Therefore, CEUS can be used to observe and predict the occurrence of sepsis related AKI.
Ethics committee of Sir Run Run Shaw Hospital, an affliated hospital of Zhejiang University, Medical College, 02/08/2017, ref:2016C91401
This is a prospective observational study. Patients diagnosed with sepsis were included in this study and divided into AKI and non-AKI groups based on the AKIN criteria. Conventional ultrasound scan and contrast-enhanced ultrasound examination are measured at 0 day, 1 day, 3 day, and 7 day after admitted to the emergency intensive care unit (EICU).
Primary study design
Secondary study design
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet: email@example.com
Sepsis, severe sepsis and septic shock
This study is observational and uses CEUS to dynamically detect the changes in renal microcirculation perfusion in the AKI and non-AKI groups. If the problem about renal microcirculation perfusion was found through CEUS, they would be treated as soon as possible.
Patients diagnosed with sepsis are included in this study and divided into AKI and non-AKI groups based on the AKIN criteria. Conventional ultrasound scan and contrast-enhanced ultrasound examination are measured at day 0, 1 day, 3 day, and 7 day after admitted to the emergency intensive care unit (EICU).
Primary outcome measure
Contrast-enhanced ultrasound examination results will be measured using the the time-intensity curve (TIC) at day 0, 1, 3 and 7 following EICU entry.
Secondary outcome measures
The flow sheet of intensive care unit, routine hematology and biochemistry profile will be measured manually every day.The patient's survival status will be measured using hospital outpatient visits or telephone interviews at 1 months, 3 months after discharge.
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Patients with sepsis, severe sepsis and septic shock can be admitted for the enrollment if they were over 18 years old
2. Sepsis is defined as an acute change in total SOFA score ≥ 2 points as a result of anti-inflammatory function. The definition of septic shock is sepsis with persistent hypotension, requiring vasopressors for the maintenance of mean arterial pressure (MAP) ≥65 mmHg and with serum lactate level > 2 mmol/L (18mg/dL), inspite of the administration of adequate volume.
Target number of participants
Participant exclusion criteria
1. EICU stay less than 24 hours or refuse related salvage treatment
2. Patients with chronic kidney disease and long-term hemodialysis
3. Critically ill patient who had already started RRT due to AKI before EICU admission
4. Past history of kidney transplantation
5. AKI caused by obstructive causes
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Sir Run Run Shaw Hospital affiliated to Zhejiang University
The emergency intensive care unit (EICU) of the Emergency Department
Zhejiang Provincial Natural Science Foundation of China
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
We planned publication in a high-impact peer reviewed journal and the publish date will be planned around one year after our overall trial end date.
IPD sharing statement:
The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository. Website: http://www.medresman.org/login.aspx. To receive the details of participant data, contact firstname.lastname@example.org for the account and password. This website will be available for all the time. There were no comments on data anonymisation, any ethical or legal restrictions, and any additional comments.
Intention to publish date
Participant level data
Stored in repository
Basic results (scientific)
2019 protocol in https://pubmed.ncbi.nlm.nih.gov/31362958/ (added 27/07/2020)